Abstract

To investigate the effects of high-quality intervention in conjunction with octreotide therapy in treating acute severe pancreatitis. A total of 140 patients diagnosed with acute severe pancreatitis, who received treatment at our hospital from June 2021 to June 2023, were randomly allocated into an observation group and a control group. Both groups were treated with regular interventions, while the observation group received high-quality intervention in addition to conventional symptomatic supportive treatment and octreotide therapy. After a 10 d treatment period, the assessment of treatment effectiveness encompassed factors such as the time taken for symptoms to disappear, patient satisfaction with interventions, and the incidence of adverse reactions. Comparing to the control group, the observation group displayed significant superiority in overall treatment effectiveness (p<0.05). Moreover, the observation group exhibited considerably reduced durations for the disappearance of abdominal pain, abdominal distension, nausea, and vomiting, and also experienced a quicker restoration of normal body temperature when compared to the control group (p<0.05). Furthermore, patients in the observation group expressed markedly greater satisfaction with interventions during their treatment. The occurrence of adverse reactions, such as leukopenia, anorexia, and rash, was notably lower in the observation group than in the control group (p<0.05). High-quality intervention in conjunction with octreotide therapy demonstrates excellent efficacy in managing acute severe pancreatitis. It significantly improves the overall treatment effectiveness, accelerates the resolution of clinical symptoms, enhances patient satisfaction with interventions, and reduces the incidence of adverse reactions. This approach is worth promoting and implementing.